Silver Spring, Maryland – The Food and Drug Administration has taken a significant step in the reconsideration of a common over-the-counter decongestant that has long been deemed ineffective for relieving nasal congestion. This move follows a thorough evaluation by the FDA, leading to a proposed order to remove oral phenylephrine from the list of approved drugs for over-the-counter products.

Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, emphasized the agency’s commitment to ensuring the safety and effectiveness of medications in a recent statement regarding the proposed removal of oral phenylephrine. The FDA’s decision is backed by a review of available data and recommendations from an advisory committee, highlighting the importance of evidence-based decision-making in drug regulation.

The FDA’s proposal marks the beginning of a process that will include a public comment period to gather feedback on the potential removal of phenylephrine from over-the-counter products. If the FDA’s initial conclusion that the drug is ineffective remains unaltered after the comment period, the order will be finalized, giving drug manufacturers a grace period to reformulate their products.

The reconsideration of phenylephrine dates back several years, tracing its origins to 2006 when the decongestant gained popularity following restrictions on pseudoephedrine due to concerns about its use in the production of methamphetamine. Subsequent evaluations of phenylephrine by an FDA panel and large-scale studies conducted by pharmaceutical companies failed to demonstrate significant benefits of the drug over a placebo, raising doubts about its effectiveness in treating nasal congestion.

As the FDA continues to reevaluate the use of phenylephrine in over-the-counter products, the proposed removal of the drug underscores the importance of scientific evidence in shaping drug regulation policies. The decision to abandon oral doses of phenylephrine reflects a commitment to prioritizing the safety and efficacy of medications available to consumers.